| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826400 | Current Opinion in Pharmacology | 2012 | 6 Pages |
Abstract
⺠N-Ras and K-Ras resistant to FTIs as a consequence of alternative geranylgeranylation. ⺠Minimal clinical activity of FTIs in phase I-III trials. ⺠RASGRP1/APTX-gene expression as predictor of response to tipifarnib in AML.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Sarah A Holstein, Raymond J Hohl,